focus -WSS

focus

author：hotspot 2025-09-27 06:09:37 - browse：58

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： HHS's proposed rule does nothing to address the climate crisis

WSS

AI for drug discovery: Experts on separating hype from reality

Lack of darker skin in textbooks, journals harms patients of color

Has Bernie Sanders reached the limit of his pharma bullying effort?

Empower primary care with adequate payments and technology

Lawmakers grill UnitedHealth CEO on Change cyberattack

Twill hunts for pharma partner to market its depression app

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

Sports medicine is finally prioritizing gender equality

AltruBio raises $225 million to develop ulcerative colitis drug

As demand for Covid shots wanes, Moderna seeks its next success

HHS's proposed rule does nothing to address the climate crisis

Malaria cases in Florida and Texas: Here’s what you need to know

Deliver public health messages at the right time

After affirmative action ruling, medical educators look to 'holistic review'

A look at other Americans who have crossed into North Korea over the years

Heart attack and stroke risk calculators need revising

Welsh Carson private equity firm escapes from FTC antitrust case

knowledge

A Theranos scientist

Biden administration sends mixed signals on US soldier who crossed into North Korea

Chemotherapy before breast cancer surgery might fuel metastasis

Study: Hearing aids may slow cognitive decline in those at risk

Brain technologies pose threats that are all too real, experts warn

HHS's proposed rule does nothing to address the climate crisis

knowledge

hotspot

leisure time

focus